Divarasib (GDC-6036) is an experimental
anticancer An anticarcinogen (also known as a carcinopreventive agent) is a substance that counteracts the effects of a carcinogen or inhibits the development of cancer. Anticarcinogens are different from anticarcinoma agents (also known as anticancer or ant ...
drug which acts as an inhibitor of the G12C mutant form of
Kirsten rat sarcoma virus (KRAS), an
oncogene
An oncogene is a gene that has the potential to cause cancer. In tumor cells, these genes are often mutated, or expressed at high levels. commonly present in several forms of cancer. It is in early stage clinical trials against various types of cancer, including colorectal cancer, lung cancer and advanced solid tumors.
See also
*
ACBI3
ACBI3 is an experimental anticancer drug which is one of the first examples of a proteolysis targeting chimera or PROTAC. It is a bifunctional molecule with two halves joined by a linker; one half binds to a protein found in various forms of can ...
*
Adagrasib
Adagrasib, sold under the brand name Krazati, is an anticancer medication used to treat non-small cell lung cancer. Adagrasib is an inhibitor of G12C mutated KRAS GTPase. It is taken by mouth. It is being developed by Mirati Therapeutics.
Th ...
*
MRTX1133
MRTX1133 is an investigational drug that targets the G12D mutation in KRAS dependent cancers. MRTX1133 was in a phase 1/2 clinical trial for the treatment of solid tumors, however the study was terminated in Q1 2025. MRTX1133 is considered to be ...
*
Olomorasib
Olomorasib (LY3537982) is an experimental anticancer drug which acts as an inhibitor of the G12C mutant form of Kirsten rat sarcoma virus (KRAS), an oncogene commonly present in several forms of cancer. It is in early stage clinical trials again ...
*
RMC-9805
RMC-9805 is an investigational drug that selectively targets the G12D mutation in KRAS dependent cancers. RMC-9805 functions as molecular glue that forms a non-covalent ligand-mediated protein-protein interaction between cyclophilin A and GTP- ...
*
Sotorasib
Sotorasib, sold under the brand names Lumakras and Lumykras, is an anti-cancer medication used to treat non-small-cell lung cancer. It targets a specific mutation, G12C, in the protein K-Ras encoded by gene KRAS which is responsible for vario ...
References
{{reflist
Experimental cancer drugs
Amines
Trifluoromethyl compounds
Pyridines
Chloroarenes
Fluoroarenes
Ureas
Pyrrolidines
Quinazolines
Piperazines
Acrylamides